TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7011467
Drug: Dipyridamole-ASA combinations
Normalized name: aspirin / dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole-ASA combinations with ASA doses of 0.5 to 0.8 mg/kg
Study: 7011467
Drug: Dipyridamole-ASA combinations
Normalized name: aspirin / dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole-ASA combinations with ASA doses between 2.6 to 5.7 mg/kg
Study: 31029154
Drug: TLP0-001 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLP0-001 in combination with S-1
Study: 31029154
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with S-1
Study: 29795561
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments (not rhTM)
Study: 19757018
Drug: Diaphragm and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm and Replens lubricant gel
Study: 6776577
Drug: Alcohol (0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.65 g/kg)
Study: 21850690
Drug: Steroid-free immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free immunosuppression (arm 3)
Study: 17960954
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy for treatment-naive patients (lamivudine plus adefovir)
Study: 15578509
Drug: Conventional percutaneous
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional percutaneous ethanol injection (PEI)
Study: 15578509
Drug: Higher-dose percutaneous
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose percutaneous ethanol injection (PEI)
Study: 2896126
Drug: Intravenous chlordesmethyldiazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chlordesmethyldiazepam (1 mg)
Study: 2896126
Drug: Oral chlordesmethyldiazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chlordesmethyldiazepam (tablets)
Study: 2896126
Drug: Oral chlordesmethyldiazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chlordesmethyldiazepam (drops)
Study: 17996006
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 microg/kg IV before remifentanil infusion (Group Pre)
Study: 17996006
Drug: Placebo before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before remifentanil infusion (Group Post)
Study: 10985648
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of rifampicin
Study: 1511814
Drug: Immediate injection
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate injection sclerotherapy (group A)
Study: 6396365
Drug: Routine continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine continuous i.v. heparin treatment (1000 units/h)
Study: 24657991
Drug: Intervention Condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Condition (IC): Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Study: 24657991
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care (UC): Printed patient education material and hypertension treatment guidelines for physicians.
Study: 24657991
Drug: Intervention Condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Condition (IC) in patients without diabetes mellitus: Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Study: 24657991
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care (UC) in patients without diabetes mellitus: Printed patient education material and hypertension treatment guidelines for physicians.
Study: 24657991
Drug: Intervention Condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Condition (IC) in small-sized community health centers: Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Study: 24657991
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care (UC) in small-sized community health centers: Printed patient education material and hypertension treatment guidelines for physicians.
Study: 15543117
Drug: A combination
Normalized name: Enema combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of inhaled medical air and titrated intravenous midazolam
Study: 15543117
Drug: A combination
Normalized name: Enema combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of inhaled 40% nitrous oxide in oxygen and titrated intravenous midazolam
Study: 15543117
Drug: A combination
Normalized name: Enema combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of an inhaled mixture of 0.3% sevoflurane and 40% nitrous oxide in oxygen with titrated intravenous midazolam
Study: 11463590
Drug: Inhibition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibition of deep inspiration during methacholine inhalation
Study: 11463590
Drug: Allowed deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allowed deep inspiration during methacholine inhalation
Study: 7994787
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg FARM by intravesical instillation every 2-4 weeks for 1 year
Study: 7994787
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ADR by intravesical instillation every 2-4 weeks for 1 year
Study: 7994787
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg FARM
Study: 7994787
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ADR
Study: 25916132
Drug: Intravenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous laser therapy (ILIB‐405) along with traditional drug treatment (proton pump inhibitors, antacids, prokinetics) in the main group (70 patients).
Study: 25916132
Drug: Traditional drug
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional drug treatment (control group, 30 patients).
Study: 25916132
Drug: Intravenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous laser therapy (ILIB‐405) along with traditional drug treatment in the main group (70 patients).
Study: 17401693
Drug: Phosphate supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate supplement
Study: 15321804
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg), vitamin B‐12 (0.4 mg)
Study: 15321804
Drug: Vitamin B‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B‐6 (40 mg)
Study: 15321804
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg) and vitamin B‐12 (0.4 mg) with additional folic acid (5 mg/d) for the first 2 weeks
Study: 11254913
Drug: Combination hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination hormone replacement therapy (17beta-estradiol plus medroxyprogesterone acetate)
Study: 11254913
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) alone (either 17beta-estradiol (1 mg) or conjugated equine estrogens (CEE) (0.625 mg))
Study: 2196149
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg over 8 hr for 5 days or longer
Study: 160237
Drug: Diazepam 0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.16 mg kg‐1
Study: 25492571
Drug: Remifentanil target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil target concentration 0 ng/ml
Study: 25492571
Drug: Remifentanil target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil target concentration 1 ng/ml
Study: 25492571
Drug: Remifentanil target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil target concentration 2 ng/ml
Study: 19602786
Drug: EE/CA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/CA plus metformin (1,700 mg, cyproterone acetate 2 mg, ethinylestradiol 35 microg)
Study: 19602786
Drug: EE/CA (cyproterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/CA (cyproterone acetate 2 mg, ethinylestradiol 35 microg)
Study: 14678372
Drug: Solifenacin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 20 mg
Study: 9825973
Drug: Dexamethasone (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.25 mg kg(‐1) b.i.d. on d 1‐7; 0.12 mg kg(‐1) b.i.d. on d 8‐14; 0.05 mg kg(‐1) b.i.d. on d 15‐21; 0.02 mg kg(‐1) b.i.d. on d 22‐28)
Study: 3881327
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid 750 mg daily
Study: 656270
Drug: Clofibrate 2
Normalized name: clofibrate 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate 2 g daily
Study: 26033312
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg·kg(‐1) (0.8 ml·kg(‐1))
Study: 26033312
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 1 μg·kg(‐1)
Study: 26033312
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 2 μg·kg(‐1)
Study: 26033312
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg·kg(‐1)
Study: 26033312
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 1 μg·kg(‐1) and 2 μg·kg(‐1)
Study: 23868620
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic Acid (UDCA) 300-450 mg/d
Study: 20469779
Drug: R +
Normalized name: Immune 24 Hour +
Approvals — FDA: no, EMA: no, PMDA: no
Description: R + G; basal‐bolus regular and glargine insulin (R‐R‐R‐G)
Study: 8901660
Drug: 650 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg/d aspirin
Study: 6190548
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-dose cis-platinum, Oncovin (vincristine) and bleomycin (COB)
Study: 29996127
Drug: Reduced fetuin‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced fetuin‐A concentrations (g/L)
Study: 28807912
Drug: MHAA4549A (3,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAA4549A (3,600 mg)
Study: 28807912
Drug: Oseltamivir (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (standard oral dose)
Study: 26611872
Drug: Concurrent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exercise training
Study: 9076465
Drug: SR-alfuzosin 5
Normalized name: alfuzosin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR-alfuzosin 5 mg twice daily
Study: 7690956
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (160 mg/day)
Study: 3530572
Drug: Bevantolol, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol, 150 mg
Study: 3530572
Drug: Propranolol, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 80 mg
Study: 24902407
Drug: Oscillating-rotating power
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oscillating-rotating power brush (Oral-B Professional Care 1000)
Study: 19877824
Drug: GaAs laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaAs laser therapy
Study: 16152824
Drug: Ginkgolide nebulised
Normalized name: Ginkgolide A
DrugBank: Ginkgolide A (DB06743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgolide nebulised inhalation 10 mg/ml, twice daily, for 6 weeks
Study: 16152824
Drug: Cromlyn sodium
Normalized name: Cromolyn Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromlyn sodium nebulised inhalation 20 mg/10 ml, twice daily, for 6 weeks
Study: 16152824
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 10 ml, twice daily, for 4 weeks
Study: 11052317
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy with omeprazole 20 mg once a day for three months
Study: 11052317
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with omeprazole 20 mg once a day for three months
Study: 8644692
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg elemental Ca/d as calcium citrate malate
Study: 1725016
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 or 5 mg twice daily)
Study: 6339292
Drug: Halometasone/triclosan cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halometasone/triclosan cream (0.05% halometasone and 1% triclosan)
Study: 6339292
Drug: Betamethasone dipropionate/gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone dipropionate/gentamicin sulphate cream (0.05% betamethasone dipropionate and 0.1% gentamicin sulphate)
Study: 31056413
Drug: No anti-platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-platelet therapy
Study: 18405377
Drug: Mental practice-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental practice-based rehabilitation training (six-week, individually tailored therapy regime)
Study: 12211224
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg bid)
Study: 12211224
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg bid) and Diclofenac (75 mg bid)
Study: 10761326
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral contraceptive pill (OCs)
Study: 1466576
Drug: 2 gm
Normalized name: Algiderm 2 gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 gm dipirone plus 20 mg hyoscine N‐butylbromide
Study: 334471
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg flurbiprofen
Study: 6722830
Drug: 1 X
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 X 10(6) units of partially purified human leukocyte (alpha) interferon by daily im injection for 42 days
Study: 6722830
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 10(6) units of partially purified human leukocyte (alpha) interferon by daily im injection for 42 days
Study: 6722830
Drug: 9 X
Normalized name: TachoSil 1.9 X 1.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 X 10(6) units of partially purified human leukocyte (alpha) interferon by daily im injection for 42 days
Study: 27737636
Drug: Lubiprostone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (24 mcg) + 2 L PEG (GrB)
Study: 27737636
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 2 L PEG (GrA)
Study: 27737636
Drug: Lubiprostone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (24 mcg) + 1.5 L PEG (GrC)
Study: 27737636
Drug: Lubiprostone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (24 mcg) + 1 L PEG (GrD)
Study: 12442956
Drug: Heliox-driven bronchodilator
Normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heliox-driven bronchodilator (HDBD)
Study: 12442956
Drug: Air-driven bronchodilator
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-driven bronchodilator (ADBD)
Study: 9809623
Drug: Pentoxifylline and
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline and ciprofloxacin (PC) therapy for 12 weeks
Study: 9809623
Drug: Pentoxifylline and
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline and ciprofloxacin with dexamethasone (PCD) therapy
Study: 9809623
Drug: PC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC therapy
Study: 1974688
Drug: Formoterol MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol MDI (2 X 12 micrograms) during 3-month monotherapy
Study: 14658
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg and 20 mg)
Study: 7083724
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (15 mg) in supine position (part A)
Study: 7083724
Drug: Evening dose
Normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dose of midazolam (part C)
Study: 7083724
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose of midazolam (part B)
Study: 18343245
Drug: Fluvastatin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin XL 80 mg/d + Ezetimibe 10 mg/d
Study: 18343245
Drug: Fluvastatin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin XL 80 mg/d
Study: 12784090
Drug: Testosterone 50
Normalized name: testosterone 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 50 mg monthly injections
Study: 12784090
Drug: Oxandrolone at
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone at a weekly dose of 0.7 mg/kg
Study: 12784090
Drug: Testosterone 25
Normalized name: testosterone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 25 mg monthly injections
Study: 10573656
Drug: BCG high
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG high dose (0.1 mg/0.1 ml)
Study: 10573656
Drug: BCG low
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG low dose (0.01 mg/0.1 ml)
Study: 8824687
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg orally)
Study: 8824687
Drug: Yohimbine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (0.1 mg kg‐1 intravenously)
Study: 8824687
Drug: Yohimbine +
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine + Naloxone (0.8 mg intravenously)
Study: 2061684
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol and estriol (2:1 ratio), 4 mg/day for 21 days (Group A)
Study: 2061684
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol and estriol (2:1 ratio), 4 mg/day for 28 days (Group B)
Study: 2061684
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol and estriol (2:1 ratio), 4 mg/day for 35 days (Group C)
Study: 6340274
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical management (intravenous methylprednisolone)
Study: 25208590
Drug: Aspirin intake
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin intake at bedtime (80 mg)
Study: 25208590
Drug: Aspirin intake
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin intake on awakening (80 mg)
Study: 17823506
Drug: Pyridoxamine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxamine 50 mg twice daily in PYR-206; escalated to 250 mg twice daily in PYR-205/207
Study: 17823506
Drug: Pyridoxamine 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxamine 250 mg twice daily in PYR-205/207
Study: 7042559
Drug: Imipramine pamoate
Normalized name: Imipramine Pamoate
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine pamoate (single dose of 150 mg)
Study: 7042559
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride (divided dose of 150 mg)
Study: 21938072
Drug: Mannooligosaccharides (MOS)
Normalized name: fructooligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannooligosaccharides (MOS) 4 g/day
Study: 10343192
Drug: Intraperitoneal carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraperitoneal carboplatin (CBP) 350 mg/m2 plus intravenous cyclophosphamide (CTX) 600 mg/m2
Study: 10343192
Drug: Intravenous carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous carboplatin (CBP) 350 mg/m2 plus intravenous cyclophosphamide (CTX) 600 mg/m2
Study: 7548495
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg single dose
Study: 1900983
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of green coffee extract
Study: 1900983
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) pretreatment (80 mg)
Study: 31861026
Drug: Valsartan-amlodipine single-pill
Normalized name: valsartan, amlodipine and hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan-amlodipine single-pill combination (SPC)
Study: 31861026
Drug: Valsartan and
Normalized name: valsartan and aliskiren
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan and amlodipine combination (Control)
Study: 28891056
Drug: Remifentanil target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil target-controlled infusion using the Minto model
Study: 25735200
Drug: Trauma-informed integrative
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-informed integrative treatment for PTSD/SUD
Study: 19376304
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR 2-3)